Synthesis, anticancer activity, structure–activity relationship and binding mode of interaction studies of substituted pentanoic acids / Sanchita Dutta, Amit Kumar Halder, Nilanjan Adhikari, Sk. Abdul Amin, Sanjib Das, Achintya Saha, Tarun Jha
Aim:Simultaneous inhibition of MMP-2 and HDAC8 may be an effective strategy to target cancer.Methodology:In continuation of our earlier efforts, a series of substituted pentanoic acids (1–18) were synthesized and checked for their biological activity along with some earlier reported compounds (19–35).Results:Compounds18and31were found to induce apoptosis effectively in a dose-dependent fashion in Jurkat-E6.1 cell line. They reduced the expression of both MMP-2 and HDAC8 effectively.31also produced prominent intensity of fluorescence to bring nick in Jurkat-E6.1 cells.31also showed cellular arrest in sub-G0 phase.Conclusion:Such compounds may be useful to battle against cancer. Aim: Methodology: 1 18 19 –35 Results: 18 31 31 31 Conclusion.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2019 |
|---|---|
| Erschienen: |
2019 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:11 |
|---|---|
| Enthalten in: |
Future medicinal chemistry - 11(2019), 14, Seite 1679- |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Dutta, Sanchita [VerfasserIn] |
|---|
| Links: |
FID Access [lizenzpflichtig] |
|---|
| Umfang: |
1 Online-Ressource (24 p) |
|---|
| doi: |
10.4155/fmc-2018-0361 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
KFL001069209 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | KFL001069209 | ||
| 003 | DE-627 | ||
| 005 | 20230430081614.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 210608s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.4155/fmc-2018-0361 |2 doi | |
| 035 | |a (DE-627)KFL001069209 | ||
| 035 | |a (KFL)prod_FICIBQ_10.4155/fmc-2018-0361 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 084 | |a PHARM |q DE-84 |2 fid | ||
| 100 | 1 | |a Dutta, Sanchita |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Synthesis, anticancer activity, structure–activity relationship and binding mode of interaction studies of substituted pentanoic acids |c Sanchita Dutta, Amit Kumar Halder, Nilanjan Adhikari, Sk. Abdul Amin, Sanjib Das, Achintya Saha, Tarun Jha |
| 264 | 1 | |c 2019 | |
| 300 | |a 1 Online-Ressource (24 p) | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Aim:Simultaneous inhibition of MMP-2 and HDAC8 may be an effective strategy to target cancer.Methodology:In continuation of our earlier efforts, a series of substituted pentanoic acids (1–18) were synthesized and checked for their biological activity along with some earlier reported compounds (19–35).Results:Compounds18and31were found to induce apoptosis effectively in a dose-dependent fashion in Jurkat-E6.1 cell line. They reduced the expression of both MMP-2 and HDAC8 effectively.31also produced prominent intensity of fluorescence to bring nick in Jurkat-E6.1 cells.31also showed cellular arrest in sub-G0 phase.Conclusion:Such compounds may be useful to battle against cancer. Aim: Methodology: 1 18 19 –35 Results: 18 31 31 31 Conclusion | ||
| 700 | 1 | |a Halder, Amit Kumar |e verfasserin |4 aut | |
| 700 | 1 | |a Adhikari, Nilanjan |e verfasserin |4 aut | |
| 700 | 1 | |a Amin, Sk. Abdul |e verfasserin |4 aut | |
| 700 | 1 | |a Das, Sanjib |e verfasserin |4 aut | |
| 700 | 1 | |a Saha, Achintya |e verfasserin |4 aut | |
| 700 | 1 | |a Jha, Tarun |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Future medicinal chemistry |d London : Future Science, 2009 |g 11(2019), 14, Seite 1679- |h Online-Ressource |w (DE-627)KFL000006157 |w (DE-600)2572258-X |w (DE-576)398101442 |x 1756-8927 |7 nnns |
| 773 | 1 | 8 | |g volume:11 |g year:2019 |g number:14 |g pages:1679- |
| 856 | 4 | 0 | |u http://pharmazie.proxy.fid-lizenzen.de/fid/future-medicine-ejournals-pharmazie/doi.org/10.4155/fmc-2018-0361 |m X:KFL |x Resolving-System |y FID Access |z lizenzpflichtig |
| 912 | |a GBV_KFL | ||
| 912 | |a FID-PHARM | ||
| 912 | |a SSG-OLC-PHA | ||
| 935 | |i IMPORT_0628_prod_FICIBQ_03 | ||
| 951 | |a AR | ||
| 952 | |d 11 |j 2019 |e 14 |h 1679- | ||